(SIBN) Si-Bone - Overview
Stock: Implants, Screws, 3D-Printed, Titanium, Sacroiliac
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 49.3% |
| Relative Tail Risk | -11.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.06 |
| Alpha | -27.19 |
| Character TTM | |
|---|---|
| Beta | 0.799 |
| Beta Downside | 0.655 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.72% |
| CAGR/Max DD | -0.04 |
Description: SIBN Si-Bone December 25, 2025
SI-BONE, Inc. (NASDAQ:SIBN) develops and sells minimally invasive implant systems that treat sacroiliac (SI) joint dysfunction, pelvic trauma, and related spinal-fusion indications. Its portfolio includes the iFuse-3D titanium implant with a 3-D-printed porous surface, the iFuse TORQ line of threaded implants for trauma and fusion, the iFuse Bedrock Granite system for sacropelvic fixation, and iFuse INTRA biologic products. The company reaches surgeons primarily through a direct sales force complemented by third-party agents and resellers, and it has operated as a public entity since its 2008 incorporation in Santa Clara, California.
Key recent metrics (FY 2024) show revenue of approximately $112 million, a 30 % year-over-year increase in iFuse-3D unit sales, and a cash runway of roughly $250 million, reflecting strong adoption amid a growing elderly population and expanding Medicare reimbursement for minimally invasive spinal procedures. The broader musculoskeletal device market is projected to grow at a 6-7 % CAGR through 2028, driven by rising prevalence of chronic low-back pain and a shift toward outpatient surgical settings-both favorable tailwinds for SI-BONE’s product strategy.
If you want a more granular financial and valuation analysis, the ValueRay platform offers a comprehensive model for SIBN that can help you assess the upside potential under different growth scenarios.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -21.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.05 > 0.02 and ΔFCF/TA 6.58 > 1.0 |
| NWC/Revenue: 95.23% < 20% (prev 114.0%; Δ -18.77% < -1%) |
| CFO/TA -0.01 > 3% & CFO -1.23m > Net Income -21.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (43.2m) vs 12m ago 3.53% < -2% |
| Gross Margin: 79.62% > 18% (prev 0.78%; Δ 7884 % > 0.5%) |
| Asset Turnover: 83.93% > 50% (prev 69.18%; Δ 14.75% > 0%) |
| Interest Coverage Ratio: -6.79 > 6 (EBITDA TTM -13.6m / Interest Expense TTM 2.79m) |
Altman Z'' -9.20
| A: 0.79 (Total Current Assets 210.8m - Total Current Liabilities 26.4m) / Total Assets 234.3m |
| B: -1.91 (Retained Earnings -448.6m / Total Assets 234.3m) |
| C: -0.08 (EBIT TTM -19.0m / Avg Total Assets 230.6m) |
| D: -7.21 (Book Value of Equity -447.8m / Total Liabilities 62.1m) |
| Altman-Z'' Score: -9.20 = D |
Beneish M -3.14
| DSRI: 0.86 (Receivables 26.5m/24.9m, Revenue 193.6m/157.0m) |
| GMI: 0.98 (GM 79.62% / 77.70%) |
| AQI: 0.91 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.23 (Revenue 193.6m / 157.0m) |
| TATA: -0.09 (NI -21.8m - CFO -1.23m) / TA 234.3m) |
| Beneish M-Score: -3.14 (Cap -4..+1) = AA |
What is the price of SIBN shares?
Over the past week, the price has changed by -5.97%, over one month by -23.58%, over three months by +2.63% and over the past year by -9.78%.
Is SIBN a buy, sell or hold?
- StrongBuy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SIBN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.4 | 62.9% |
| Analysts Target Price | 25.4 | 62.9% |
| ValueRay Target Price | 15.4 | -1.5% |
SIBN Fundamental Data Overview February 02, 2026
P/B = 4.1822
Revenue TTM = 193.6m USD
EBIT TTM = -19.0m USD
EBITDA TTM = -13.6m USD
Long Term Debt = 35.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.13m USD (from shortTermDebt, last quarter)
Debt = 36.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.3m USD (from netDebt column, last quarter)
Enterprise Value = 610.5m USD (719.4m + Debt 36.8m - CCE 145.7m)
Interest Coverage Ratio = -6.79 (Ebit TTM -19.0m / Interest Expense TTM 2.79m)
EV/FCF = -57.50x (Enterprise Value 610.5m / FCF TTM -10.6m)
FCF Yield = -1.74% (FCF TTM -10.6m / Enterprise Value 610.5m)
FCF Margin = -5.48% (FCF TTM -10.6m / Revenue TTM 193.6m)
Net Margin = -11.24% (Net Income TTM -21.8m / Revenue TTM 193.6m)
Gross Margin = 79.62% ((Revenue TTM 193.6m - Cost of Revenue TTM 39.5m) / Revenue TTM)
Gross Margin QoQ = 79.84% (prev 79.80%)
Tobins Q-Ratio = 2.61 (Enterprise Value 610.5m / Total Assets 234.3m)
Interest Expense / Debt = 1.82% (Interest Expense 670.0k / Debt 36.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -15.0m (EBIT -19.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.97 (Total Current Assets 210.8m / Total Current Liabilities 26.4m)
Debt / Equity = 0.21 (Debt 36.8m / totalStockholderEquity, last quarter 172.1m)
Debt / EBITDA = -0.76 (negative EBITDA) (Net Debt 10.3m / EBITDA -13.6m)
Debt / FCF = -0.97 (negative FCF - burning cash) (Net Debt 10.3m / FCF TTM -10.6m)
Total Stockholder Equity = 169.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.43% (Net Income -21.8m / Total Assets 234.3m)
RoE = -12.86% (Net Income TTM -21.8m / Total Stockholder Equity 169.2m)
RoCE = -9.26% (EBIT -19.0m / Capital Employed (Equity 169.2m + L.T.Debt 35.5m))
RoIC = -7.32% (negative operating profit) (NOPAT -15.0m / Invested Capital 204.7m)
WACC = 8.50% (E(719.4m)/V(756.3m) * Re(8.86%) + D(36.8m)/V(756.3m) * Rd(1.82%) * (1-Tc(0.21)))
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.16%
Fair Price DCF = unknown (Cash Flow -10.6m)
EPS Correlation: 95.70 | EPS CAGR: 95.29% | SUE: 4.0 | # QB: 4
Revenue Correlation: 96.91 | Revenue CAGR: 19.14% | SUE: 2.12 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.15 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=7
EPS next Year (2026-12-31): EPS=-0.49 | Chg30d=-0.002 | Revisions Net=-3 | Growth EPS=+6.9% | Growth Revenue=+14.5%